Germany and France set to U-turn on AstraZeneca jab for over-65s

Germany and France ‘WILL give AstraZeneca jab for over-65s’ in major U-turn aimed at speeding up shambolic vaccine drive

  • Health chiefs in Germany say they could update advice on vaccine ‘very soon’
  • Officials in France have also suggested they could now change policy on jab
  • Both countries had previously stopped the jab for use on those aged over 65
  • But recent real-world study showed jab drastically reduced hospital admissions 

Germany and France look set to approve the AstraZeneca Covid jab for the over 65s in a major U-turn aimed at speeding up their stuttering vaccine drives.

In an ignominious climb-down, health chiefs in both countries have now suggested they could update their policies for the Oxford University researched jab – after initially refusing to give it to those over 65.

Officials in Germany previously raised doubts about the vaccine’s effectiveness amid reports – rubbished by AstraZeneca – that the vaccine was just 8 per cent effective at protecting those in older age groups.

France’s Emmanuel Macron even went as far as to claim the jab was ‘quasi-ineffective’ at protecting the elderly. 

But as vaccine rollout programmes in both countries continue to lag behind Britain, and with new data showing the AstraZeneca jab is effective in protecting the elderly, France and Germany now look set to U-turn. 

Germany and France look set to approve the AstraZeneca Covid jab for the over 65s in a major U-turn aimed at speeding up their shambolic vaccine drives. Pictured: A near empty vaccination centre in Germany earlier this month


In a ignominious climbdown, health chiefs in both countries have now suggested they could update their policies for the Oxford University researched jab after initially refusing to give it to the over 65s.

Thomas Mertens, the head of the country’s vaccine committee last night said it would would ‘very soon’ update its recommendation on the jab.

France changes its tune on AstraZeneca jabs following Ursula von der Leyen’s praise for the vaccine 

France’s government has said it wants to ‘rehabilitate’ the AstraZeneca vaccine as EU leaders try to undo the doubts they sowed about the jab which have led to low uptake despite its proven effectiveness.

The French health ministry admitted that the Oxford/AstraZeneca vaccine had an ‘image deficit’ which had led to ‘feeble’ usage of the jab, with only 107,000 people immunised with it so far.

It comes after Emmanuel Macron himself raised doubts about the jab’s effectiveness and claimed that Britain had taken a risk by authorising it so soon, while French regulators refused to approve it for over-65s.

Meanwhile the French government is considering new local restrictions to deal with a worsening Covid-19 situation as it scrambles to avoid a new national lockdown.

‘We will use all possible levers to rehabilitate the vaccine,’ the French health ministry said, according to Le Telegramme, days after real-world data in Scotland showed the AstraZeneca shot reducing Covid hospitalisations by 94 per cent.

Germany’s government is also pleading with people to take the AstraZeneca jab, while EU chief Ursula von der Leyen said that she herself would take it – despite her furious row with the drugmaker last month over missing shipments to the EU.

That struggle is set to continue into the spring with as many as 90million doses missing from AstraZeneca shipments in the second quarter of 2021.

An EU official involved in talks with the firm says AstraZeneca has warned that it may deliver only half of its promised 180million doses from April to June, having slowed supplies in January because of delays at a Belgian factory.

The new shortage could hamper the EU’s ability to meet its target of vaccinating 70 per cent of adults by summer – with Britain promising to offer one dose to 100 per cent by July 31.

The EU supply shortage is seen as one of the main reasons for a widely-criticised vaccine roll-out which is lagging far behind that in Britain.

While the UK has handed out 27.0 doses per 100 people, the EU is lagging behind on 6.2 and has not significantly sped up its progress in recent weeks.

Von der Leyen defended her policies by pointing out that the EU had handed out 27milion doses in total compared to 17million in Britain – but the bloc of 27 countries has a population more than six times larger.

She also noted that Italy had given double-doses to more people than Britain, but it has handed out far fewer doses overall.

Catching up to Britain will be made even harder if AstraZeneca shortfalls continue into the early summer, as an EU official told Reuters last night.

Von der Leyen told the Augsburger Allgemeine that ‘I would take the AstraZeneca vaccine without a second thought, just like Moderna’s and BioNTech/Pfizer’s products,’

 

And in a frank admission on German television station ZDF, he said: ‘The whole thing has somehow gone wrong.’  

Meanwhile, Alain Fischer, chairman of France’s vaccine strategy orientation council, said the country would ‘re-adjust our vaccine strategy’.

He said the rethink was in response to new data from a recent real-world study in Scotland which showed the AstraZeneca jab’s use reduced hospital admissions by 94 per cent.

It comes as the EU’s vaccine rollout continues to stall and lag behind Britain’s programme.

Latest figures show there have been 29.33 doses administered per 100,000 in the UK, compared to just 7.13 across the EU.

Germany (7.05 per 100,000 people) and France (6.34 per 100,000), both key players within the EU, are lagging behind the bloc’s average.  

Meanwhile Germany and France this week began a PR offensive in order to tackle scepticism about the effectiveness of the AstraZeneca jab.

Germany’s government this week began pleading with people to take the vaccine.

France’s government meanwhile said it wants to ‘rehabilitate’ the AstraZeneca jab – as EU leaders try to undo the doubts they sowed about its effectiveness.

Only 150,000 out of 1.5million doses of the jab had been used in Germany on Friday, with many deliberately skipping appointments after learning they would receive the Oxford vaccine.

In Berlin, the Tegel vaccination centres, which only offer the AstraZeneca jabs, say 200 people are keeping the 3,800 daily appointments, The Times reported this week.

In France, health workers have also been refusing the vaccine after President Macron’s comments during the heated row over its effectiveness.

The European Medicines Agency approved the vaccine for all adults, but both France and Germany ruled that it should not be given to the over-65s.  

After initially questioning its effectiveness, President Macron later said he would take the vaccine.

Angela Merkel caused further confusion when in an interview with Frankfurter Allgemeine Zeitung, the German chancellor said last week: ‘I am 66 years old and I do not belong to the group recommended for AstraZeneca.’ 

Though some interpreted this as a rejection of the vaccine, other commentators claim the chancellor was merely suggesting that others should get the vaccine first. 

Meanwhile EU chief Ursula von der Leyen said that she herself would take it – despite her furious row with the drugmaker last month over missing shipments to the EU.

That struggle is set to continue into the spring with as many as 90million doses missing from AstraZeneca shipments in the second quarter of 2021.

An EU official involved in talks with the firm says AstraZeneca has warned that it may deliver only half of its promised 180million doses from April to June, having slowed supplies in January because of delays at a Belgian factory.

The new shortage could hamper the EU’s ability to meet its target of vaccinating 70 per cent of adults by summer – with Britain promising to offer one dose to 100 per cent by July 31.

The EU supply shortage is seen as one of the main reasons for a widely-criticised vaccine roll-out which is lagging far behind that in Britain.

While the UK has handed out 27.0 doses per 100 people, the EU is lagging behind on 6.2 and has not significantly sped up its progress in recent weeks.

Von der Leyen defended her policies by pointing out that the EU had handed out 27milion doses in total compared to 17million in Britain – but the bloc of 27 countries has a population more than six times larger.

European Commission chief Ursula von der Leyen, pictured, says she would take the AstraZeneca vaccine despite feuding with the firm over supplies to the bloc 

This woman received the AstraZeneca vaccine in a hospital in Madrid on Tuesday – but elsewhere there has been low uptake after European scaremongering about the product 

She also noted that Italy had given double-doses to more people than Britain, but it has handed out far fewer doses overall.

Catching up to Britain will be made even harder if AstraZeneca shortfalls continue into the early summer, as an EU official told Reuters last night.

Von der Leyen told the Augsburger Allgemeine that ‘I would take the AstraZeneca vaccine without a second thought, just like Moderna’s and BioNTech/Pfizer’s products,’

But she also continued to voice doubts about the UK’s strategy of delaying second doses – a move approved by Britain’s chief medical officers – as she claimed that the EU was ‘catching up’ in the vaccine race.

AstraZeneca is producing vaccines at two plants in the UK, one in Belgium and one in the Netherlands, but is not exporting its British-made jabs under its contract with UK ministers – although it has offered the EU doses made in India and the US.

The official said AstraZeneca planned to deliver about 40million doses in the first quarter, less than half the 90million shots it was supposed to supply.

It was also due to deliver 30 million doses in the last quarter of 2020 but did not supply any shots last year as its vaccine had yet to be approved by the EU.

All told, AstraZeneca’s total supply to the EU could be about 130 million doses by the end of June, well below the 300 million it committed to deliver to the bloc by then.

AstraZeneca did not deny the EU official’s claims, but said it was striving to increase productivity in order to meet its 180million target.

‘We are hopeful that we will be able to bring our deliveries closer in line with the advance purchase agreement,’ an AstraZeneca spokesman said.

Later in the day, the firm added that its ‘most recent Q2 forecast… aims to deliver in line with its contract with the European Commission’.

‘At this stage AstraZeneca is working to increase productivity in its EU supply chain and to continue to make use of its global capability in order to achieve delivery of 180 million doses to the EU in the second quarter,’ it said.

A European Commission spokesman declined to comment on confidential talks but said the EU should have enough shots even if the AstraZeneca targets are not met.

Source: Read Full Article